Data Gaps that Create Pharma R&D Waste
13 February 2026 Category: Clinical TrialPharma R&D waste is often mistaken for scientific failure. In reality, a large portion of it is strategic and preventable.
Pharma R&D waste is often mistaken for scientific failure. In reality, a large portion of it is strategic and preventable.
The generic injectable market is not glamorous. It is not trendy either. But it prints money.
The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent cliffs are coming one after another, biologics are losing exclusivity across the world, and every pharma company wants a piece of the action.
Discover the latest trends in drug discovery and development for 2026, including AI-driven research, advanced clinical trial technologies, precision medicine innovations, and emerging pharma strategies shaping the future of healthcare.
Bottom line is, 2026 will is going to be one of the most important years for healthcare sector. So let’s dive in, and get a better look at what next year have up it’s sleeves.
Explore how Phase I drug formulations transition from lab research to human testing, shaping the foundation for safe and effective clinical development.
The global herbal medicine market is booming, and at its heart lies Traditional Chinese Medicine (TCM).
Antimicrobial resistance (AMR) is getting scary. Experts say that by 2050, it could cause 10 million deaths every year if we don’t act.
Generics and biosimilars both make drugs cheaper, but they behave very differently after a patent dies.
For pharma leaders, investors, and business development teams, these five years represent both risk and opportunity on a historic scale.